Terns Pharmaceuticals Files 8-K
Ticker: TERN · Form: 8-K · Filed: Apr 29, 2024 · CIK: 1831363
Sentiment: neutral
Topics: 8-K, SEC Filing, Regulation FD
TL;DR
Terns Pharma filed a routine 8-K, no major news.
AI Summary
Terns Pharmaceuticals, Inc. filed an 8-K on April 29, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Terns Pharmaceuticals is adhering to its reporting obligations with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not disclose any new material risks or events.
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — Registrant
- April 29, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 1065 East Hillsdale Blvd. Suite 100 (address) — Principal Executive Offices
- Foster City, California (location) — Principal Executive Offices Location
- 94404 (zip_code) — Principal Executive Offices Zip Code
- (650) 525-5535 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Terns Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on April 29, 2024.
In which state is Terns Pharmaceuticals, Inc. incorporated?
Terns Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Terns Pharmaceuticals, Inc.?
The principal executive office address is 1065 East Hillsdale Blvd., Suite 100, Foster City, California, 94404.
What is the telephone number listed for Terns Pharmaceuticals, Inc.?
The telephone number listed for Terns Pharmaceuticals, Inc. is (650) 525-5535.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-04-29 16:15:24
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TERN Nasdaq Glo
Filing Documents
- tern-20240429.htm (8-K) — 40KB
- tern-ex99_1.htm (EX-99.1) — 28KB
- img52906712_0.jpg (GRAPHIC) — 6KB
- 0000950170-24-049870.txt ( ) — 202KB
- tern-20240429.xsd (EX-101.SCH) — 26KB
- tern-20240429_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 29, 2024, Terns Pharmaceuticals, Inc. issued a press release announcing data from its ongoing Phase 1 pharmacokinetic study of TERN-701. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Terns Pharmaceuticals, Inc. on April 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TERNS PHARMACEUTICALS, INC. Date: April 29, 2024 By: /s/ Bryan Yoon Bryan Yoon Chief Operating Officer & General Counsel